RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
C-Bridge Capital, a China private equity firm with a life science focus, closed its second fund, C-Bridge Healthcare Fund II, at its $400 million cap. C-Bridge is a subsidiary of New York’s Island Capital Group, a real-estate merchant bank. C-Bridge plans to invest in late-stage companies in the fields of bio-technology, pharmaceuticals, medical devices and health care, particularly those with cross-border ambitions. C-Bridge is active in Asia-Pacific — especially China — the US and Israel. Its first healthcare fund closed in 2014 after raising $200 million.
Source: ChinaBio Today
